

HOKKAIDO UNIVERSITY

Title	Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner
Author(s)	Takayanagi, Ryo; Ohashi, Takashi; Yamashita, Eizaburo; Kurosaki, Yohei; Tanaka, Kumiko; Hakata, Yoshiyuki; Komoda, Yasumasa; Ikeda, Satoru; Tsunetsugu-Yokota, Yasuko; Tanaka, Yuetsu; Shida, Hisatoshi
Citation	Journal of Virology, 81(11), 5908-5918 https://doi.org/10.1128/JVI.02811-06
Issue Date	2007-06
Doc URL	http://hdl.handle.net/2115/27990
Rights	Copyright © 2007 American Society for Microbiology
Туре	article (author version)
File Information	JV81-11.pdf



1	Enhanced Replication of Human T-cell Leukemia Virus Type 1 in T Cells from Transgenic
2	Rats Expressing Human CRM1 That Is Regulated in a Natural Manner
3	
4	Ryo Takayanagi ¹ , Takashi Ohashi ¹ , Eizaburo Yamashita ² , Yohei Kurosaki ¹ , Kumiko
5	Tanaka ¹ , Yoshiyuki Hakata ^{1,6} , Yasumasa Komoda ³ , Satoru Ikeda ³ , Yasuko Tsunetsugu-
6	Yokota ⁴ , Yuetsu Tanaka ⁵ , Hisatoshi Shida ¹ *
7	
8	¹ Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo 060-0815, Japan
9	² Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto,
10	Japan
11	³ Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka 569-1125,
12	Japan
13	⁴ Department of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo
14	162-8640, Japan
15	⁵ Department of Immunology, Graduate School and Faculty of Medicine, University of the
16	Ryukyus, Nishihara, Okinawa 903-0215, Japan
17	⁶ Present sddress: Department of Microbiology, NYU school of Medicine, 522 First Avenue,
18	New York, New York 10016, USA
19	
20	*Corresponding author: Hisatoshi Shida, Institute for Genetic Medicine, Hokkaido University,
21	Kita-15, Nishi-7, Kita-ku, Sapporo 060-0815, Japan.
22	E-mail:hshida@igm.hokudai.ac.jp. Phone/Fax number:81-11-706-7543
23	
24	Running title: HTLV-1 replication in hCRM1 Tg rat
25	
26	Word counts Abstract: 221

27 Text: 6015

29

Abstract

30 Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T cell 31 leukemia (ATL). To develop a better animal model for the investigation of HTLV-1 infection, 32 we established a transgenic (Tg) rat carrying the human CRM1 (hCRM1) gene that encodes a 33 viral RNA transporter, which is a species-specific restriction factor. At first we found that 34 CRM1 expression is elaborately regulated through protein kinase C involving pathway during 35 lymphocyte activation initially by post-transcriptional and subsequently by transcriptional 36 manners. This fact led us to use an hCRM1 containing BAC clone, which would harbor the 37 entire regulatory and coding regions of the CRM1 gene. The Tg rats expressed hCRM1 38 protein in a manner similar to the intrinsic rat CRM1 in various organs. HTLV-1-infected T 39 cell lines derived from these Tg rats produced 100 to 10,000 fold more HTLV-1 than did T 40 cells from wild type rats, and the absolute levels of HTLV-1 were similar to those produced 41 by human T cells. We also observed enhancement of the dissemination of HTLV-1 to thymus 42 in the Tg rats after intraperitoneal inoculation, although the proviral loads were low both in 43 wild type and the Tg rats. These results support the essential role of hCRM1 in proper HTLV-44 1 replication and suggest the importance of this Tg rat as an animal model for HTLV-1.

INTRODUCTION

47	Human T-cell leukemia virus type I (HTLV-1) is etiologically associated with human adult
48	T-cell leukemia (ATL), a chronic progressive neurological disorder termed HTLV-1
49	associated myelopathy/tropical spastic paraparesis (HAM/TSP) (17, 27, 54, 55), and several
50	other human diseases (23, 40, 42, 48). Examination of the viral nucleotide sequences among
51	different disease groups has not revealed any specific determinants that distinguish a
52	particular HTLV-1 associated disease (11, 35, 67). Thus, a primary determinant of HTLV-1
53	associated disease may be host-related.
54	In order to investigate HTLV-1 infection and its related disease development in detail,
55	suitable animal models are required. HTLV-1 can immortalize simian, feline, rat, and rabbit
56	lymphocytes in vitro (2, 29, 46). HTLV-1 can also infect experimental animals, such as
57	rabbits, monkeys, and rats (2, 45, 53, 62). Using these susceptible animals, several models
58	have been developed to study HTLV-1 associated diseases. The HAM/TSP-like disease
59	model in WKA strain rats has been well established and used to dissect the pathogenic
60	mechanisms of the disease (31, 39). In contrast, only a few ATL model systems have been
61	established using rabbits and rats, but their utility is limited. For instance, the rabbit ATL
62	model shows reproducible development of an ATL-like disease in adult animals (58), but few
63	immunological studies can be performed in this animal, primarily because of the difficulty in
64	obtaining inbred strains of rabbits. In the rat models, the development of ATL-like disease
65	was observed only in newborn animals with a very short period of disease onset (64), making
66	it difficult to perform oncological and immunological studies at the same time. Kannagi and
67	Ohashi have established a rat model of ATL-like disease in which they were able to examine
68	the growth and spread of HTLV-1-infected cells, as well as assess the effects of T cells on the
69	development of the disease in T cell-deficient nude rats (51). This model system has been
70	used to assess DNA or peptide-based vaccine development (25, 52) and to study the effects of
71	Tax-directed siRNA on HTLV-1 induced tumors (50). However, since the growth of HTLV-1
72	tumors could be monitored in only immune-deficient nude rats in this model system, better
73	animal models are still necessary.

74 HTLV-1 replicates poorly in rats, which may be one of the reasons why previously 75 established models could not completely reproduce the features of HTLV-1 related diseases. 76 We have previously examined the differences in the pattern of viral gene expression between 77 human and rat T cells infected with HTLV-1. In rat cells, the levels of viral mRNAs encoding 78 the Gag and Env proteins were much lower than those encoding the Tax and Rex proteins 79 (36). Rex plays an important role in escorting unspliced and incompletely spliced viral 80 mRNAs to the cytoplasm, resulting in enhanced synthesis of viral structural proteins (5, 34, 81 69). Human CRM1 (hCRM1) is a critical factor for Rex-dependent viral mRNA export to the 82 cytoplasm and rat CRM1 (rCRM1) cannot substitute for this function (19, 22, 69). Thus, it is 83 reasonable to assume that transgenic (Tg) rats carrying the hCRM1 gene should provide a 84 better environment for HTLV-1 replication and that such animals would provide a better animal model of HTLV-1 infection. 85

86 CRM1 is involved in numerous cellular activities, suggesting its essential function in 87 viability, which is supported by the high conservation of CRM1 genes from yeast to humans 88 (37) and by the demonstration that both yeast and mammalian cells defective for CRM1 are 89 inviable (1, 15). In contrast, overexpression of CRM1 has been reported to inhibit early 90 embryogenesis in Xenopus (8). Therefore, proper expression of hCRM1 in rats will be 91 essential to produce Tg rats. However, the regulation of CRM1 expression and synthesis has 92 not yet been investigated in detail. Some immortalized cell lines have been reported to 93 maintain CRM1 protein at constant levels throughout the cell cycle, which is compatible with 94 an essential function (37), but other reports have indicated variations in the level of 95 expression of CRM1 among different tissues (28, 37), implying that the expression is 96 regulated. Therefore, we first investigated the expression profile of the CRM1 gene, 97 especially during lymphocyte activation, to determine means for the proper expression of 98 hCRM1 as a transgene. Our results indicate that expression of the CRM1 gene is elaborately 99 regulated during activation of lymphocytes, including CD4⁺ T cells, the major targets of 100 HTLV-1. These data suggested that it would be necessary to use a construct harboring the 101 entire regulatory and coding regions of CRM1 for Tg rat construction.

102	Using an artificial bacterial chromosome (BAC) clone containing the entire CRM1 gene, we
103	have established hCRM1 Tg rats and examined the proliferation of HTLV-1 in vitro and in
104	vivo. Our results demonstrate that T cell lines isolated from hCRM1 Tg rats produced 100 to
105	10,000 times more HTLV-1 Gag antigen compared to T cells from wild type control rats and
106	that Tg rats displayed a more extensive invasion of HTLV-1 into the thymus when infected
107	intraperitoneally. These results indicate the essential role of hCRM1 in proper HTLV-1
108	replication and suggest the importance of this Tg rat model as a basis for the development of
109	better HTLV-1 animal models.
110	
111	MATERIALS AND METHODS
112	
113	Cells. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors
114	using Ficoll-Hypaque (Pharmacia) or Ficoll Paque Plus (Amersham Biotechnology) density
115	centrifugation. CD4 ⁺ T lymphocytes were purified by negative selection using an
116	immunomagnetic cell sorting apparatus, the MidiMACS cell separator (Miltenyi Biotec),
117	using a cocktail of MACS MicroBeads coupled to hapten-conjugated MAbs specific for CD8,
118	CD11b, CD16, CD19, CD36, and CD56. The purity of CD4 ⁺ T cells was evaluated by flow
119	cytometry (FACSCalibur: BECTON DICKINSON) to be approximately 95% pure.
120	For activation, cells were cultured with various combinations of 50 nM phorbol 12-myristate
121	13-acetate (PMA), 100 nM ionomycin, and 10 ng/ml IL-2.
122	The HTLV-1 producing rat and human T cell lines, FPM1 and MT-2, have been described
123	previously (36, 44). HTLV-1-immortalized cell lines from wild type (Wt) or Tg rats were
124	established by cocultivating thymocytes or splenocytes with MT-2, which had been treated
125	with mitomycin C (50 μ g/ml) for 30 min at 37°C. These cells were maintained in the medium
126	supplemented with 10 U/ml of interleukin (IL)-2 (PEPROTECH EC) at the beginning of co-
127	culture. Some cell lines were eventually freed from exogenous IL-2.
128	Western blotting. Cells were lysed in ice-cold extraction buffer (10 mM Tris-HCl [pH 7.4],
129	1 mM MgCl ₂ , 0.5% NP-40) containing protease inhibitor cocktail (Complete mini; Roche
130	Diagnostics). The protein concentration of each sample was determined using a protein assay

131 kit (QB PERBIO; Pierce). The cell lysates were sonicated, or in some cases treated with

132 DNase 1 solution (Takara), then dissolved in sample buffer. The same amounts

133 (approximately 20 µg) of cell lysates were subjected to SDS-PAGE. Following

134 electrophoresis. Proteins were transferred to a nitrocellulose membrane and probed with anti-

human or rat CRM1(34), anti-β-actin (AC40; Sigma), or anti-Rex (34) antibodies followed

136 by secondary antibodies conjugated to alkaline phosphatase or horseradish peroxidase.

137 Proteins were visualized by staining with BCIP/NBT, or ECL+ (Amersham Pharmacia

138 Biotech) followed by the LAS-100 plus system (Fuji film) and evaluated by Image Gauge

139 Version 3.4 software (Fuji film).

hCRM1 mRNA quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini
Kit (Qiagen) and treated with RNase-Free DNase I (Qiagen) to minimize contamination of
chromosomal DNA. The RNA concentration was measured by absorbance at 260 nm, and
purity was ascertained by the OD 260/280 ratio and gel electrophoresis.

144 To quantify CRM1 mRNA, RNA samples (5 µg) were subjected to quantitative RT-PCR

145 with the Platinum Quantitative RT-PCR Thermoscript One Step System (Invitrogen) using

146 the forward primer 5'- GCT GAA AAC TCA ACC GAG ATG G -3' and the reverse primer

147 5'- CTG TTG CTC TTG CTG ATG CTG TA -3', and a probe (FAM-) AAA ATG CCG

148 CAG GCA TTT CGT TCA G (-TAMRA). RT-PCR was performed by incubating for 2 min

149 at 50 °C, 30 min at 60 °C, 10 min at 95 °C, and then 50 cycles of 20 s at 95 °C and 1 min at

150 62 °C in an Applied Biosystems Prism 7700 Sequence Detector Thermocycler (Applied

151 Biosystems) with Sequence Detector software (Applied Biosystems). To make standard

152 curves, the region from -943 to +38 bp of the CRM1 cDNA was amplified by PCR using

153 Human Lung Marathon Ready cDNA (Clontech) with adaptor primer-1 and 5'-

154 GCTGCATGGTCTGCTAACATT-3' and by nested PCR with adaptor primer-2 and 5'-

155 CTGCATGGTCTGCTAACATTG-3'. The PCR product was cloned into the vector pCR 2.1

156 (Invitrogen) and a 981-base single stranded RNA was synthesized *in vitro* with MegaScript

157 T7 (Ambion).

Establishment of human CRM1 transgenic rats. pBeloBAC hCRM1, which harbors the
entire human CRM1 genomic sequence including approximately 50 kb of 5' upstream

160 sequence and 10 kb of 3' downstream sequence, was microinjected into 450 fertilized one-

161 cell eggs prepared from Fischer 344/Du Crj (F344) female rats by the YS institute. Integration

162 of the transgene was confirmed by PCR using genomic DNA, which was extracted by the

- 163 PUREGENETM tissue kit (Gentra) from the rat tail, as a template with the hCRM1 specific
- 164 primer pairs: 5'-TTATGTGGCTGCAGTGTGGA-3' and 5'-
- 165 ACATACCAGGGTTCTCTGGA-3', and 5'-GTCACCTGATGTCGGGAGTT-3' and 5'-

166 GGATTACAGGTGTGAGCCA-3. All animal experiments were conducted according to the167 Guide for the Care and Use of Laboratory Animals, Institute for Genetic Medicine, Hokkaido

168 University.

169 Detection of genomic copies of hCRM1 and G3PDH. Genomic DNA was subjected to 170 PCR with the following primer pairs: hCRM1, forward primer (5'-TGA GGT CAG GAG 171 TTC AGG AT-3') and reverse primer (5'-CTC TGC CTC CTG GGT TCA A-3'); G3PDH, 172 forward primer (5'-AGA GCT GAA CGG GAA G-3') and reverse primer (5'-GGA AGA 173 ATG GGA GTT GC-3'). The PCR conditions were: 5min at 94 °C, 10 cycles of 30 s at 94 °C, 60 s at 69 °C, with a decrease of 0.5 °C/cycle, and 30 s at 72 °C, followed by 8 cycles of 174 175 30 s at 94 °C, 60 s at 65 °C, and 30 s at 72 °C and a final extension for 10 min at 72 °C. 176 Quantification of HTLV-1 proviral load by LightCycler-based real-time PCR. The 177 HTLV-1 proviral loads of HTLV-1-infected cells were quantified by real-time PCR on a 178 LightCycler PCR Instrument (Roche Diagnostics). Briefly, 20 µl of a PCR mixture in a 179 capillary tube containing each HTLV-1 pX-specific inner primer pair at 0.4 µM, 1x 180 LightCycler-FastStart SYBR Green PCR Master Mix, and 30 ng of genomic DNA was subjected to 40 cycles of denaturation (95 °C 15 s), annealing (69 °C, 10 s), and extension (72 181 182 °C, 10 s) following an initial Taq polymerase activation step (95 °C, 15 min). The copy 183 numbers of HTLV-1 provirus in the samples were estimated from a standard regression curve 184 using the LightCycler Software version 3 (Roche Diagnostics). The standard curve for HTLV-1 provirus was obtained by PCR data using 1×10^{2} to 1×10^{8} copies of pCR-pX1-4 185 plasmids, which were constructed by inserting a PCR fragment amplified with pX1 (5'-CCC 186 187 ACT TCC CAG GGT TTG GAC AGA GTC TTC-3') and pX4 (5'-GGG GAA GGA GGG

- 188 GAG TCG AGG GAT AAG GAA-3') from the genomic DNA of MT-2 cells into pCR2.1.

189 The copy numbers of HTLV-1 provirus were normalized by dividing with those of the190 G3PDH gene in the same samples.

Detection of HTLV-1 p19. Each cell line (10⁵/well) was cultured in 24-well flat-bottom
plates for 4 days. The amount of HTLV-1 p19 protein in the culture supernatant or in rat
plasma was quantified using HTLV-1/2 p19 antigen ELISA (ZeptoMetrix).
Detection of intracellular Tax and Gag protein. Cells (10⁶) were fixed with 1%
paraformaldehyde in phosphate-buffered saline (PBS) containing 20 µg/ml of lysolecithin
(Sigma) for 2 min at room temperature, centrifuged, and resuspended in cold methanol. The
cells were then sorted at 4 °C for 15 min, centrifuged, and incubated in 0.1% NP40 in PBS at

198 4 °C for 5 min. After centrifugation, the cells were stained with mouse anti-Tax MAb LT-4

199 (63) or the mouse anti-Gag MAb GIN-7 (38) followed by FITC-conjugated goat anti-mouse

IgG plus M antibody (Immunotech). Finally, the cells were washed and fixed with 1%

201 formalin in PBS prior to analysis by cell sorting.

202 Inoculation of HTLV-1 into rats. Various numbers of mitomycin C-treated or untreated

203 MT-2 cells were intraperitoneally administered to 3 to 6 week old Wt or hCRM1-Tg rats.

204 Peripheral blood samples were collected from the rats every 2 or 4 weeks after inoculation

and the presence of HTLV-1 provirus in peripheral blood cells and levels of p19 in plasma

were determined. In some experiments, rats were euthanized 1 week after inoculation and

samples were collected to assess plasma p19 concentrations, proviral loads, and the presenceof HTLV-1 provirus.

Detection of provirus in HTLV-1-infected rats. To determine the positive rate of HTLV-1
 provirus in various organs, 200 µg of genomic DNA was subjected to PCR for the

amplification of the px region of HTLV-1 as described previously (51). The first-step PCR

212 was performed with the primer pair of pX1 and pX4, followed by the second-step PCR with

213 the primer pair of pX2 (5'-CGGATACCCAGTCTACGTGTTTGGAGACTGT-3') and pX3

214 (5'-GAGCCGATAACGCGTCCATCGATGGGGGTCC-3'). The PCR conditions were:

215 activation of Taq polymerase (94 °C, 3 min); 35 cycles of denaturation (94 °C, 30 sec),

annealing (60 °C, 30 sec), and extension (72 °C, 30 sec), and a final elongation of the product

217 (72 °C, 3 min). For a nested PCR, an aliquot of the first PCR product was subjected to
218 another 35 PCR cycles with the second set of primers.

- 219
- 220

RESULTS

221

222 Regulated expression of CRM1 in lymphocytes. We first examined the level of 223 expression of CRM1 mRNA in human tissues by PCR using cDNA derived from the tissues. 224 Expression of CRM1 mRNA was variable in different tissues. Notably, CRM1 mRNA was 225 expressed at very low levels in PBMCs (data not shown). This result was unexpected because 226 PBMCs include CD4⁺ T cells, which are the targets of HIV and HTLV-1 (14). Lymphocytes 227 in the PBMC population are mainly in a resting state, leading us to hypothesize that the 228 production of CRM1 is stimulated during lymphocyte activation. Consequently, activated 229 hematopoietic cells should contain CRM1 protein at levels similar to those observed in lymphocyte derived cell lines. We prepared CD4⁺ T helper cells, macrophages, and DCs from 230 231 PBMCs, cultured them in the presence of appropriate cytokines, and compared the amount of 232 CRM1 present in these cells with amounts found in Jurkat cells, a transformed cell line that 233 constitutively expresses CRM1. Western blotting indicated that all activated lymphocyte 234 subsets and monocyte-lineage cells expressed CRM1 at levels similar to those in Jurkat cells 235 (data not shown). These results indicate that lymphocyte activation induces high levels of 236 CRM1 expression.

237 To demonstrate that CRM1 is induced during lymphocyte activation, we stimulated freshly 238 isolated PBMCs with calcium ionophore, PMA, and IL-2, and examined CRM1 levels at 239 several times by Western blotting (Figure 1A). The level of CRM1 in resting PBMCs was 240 very low. The level of CRM1 clearly increased 4 h after stimulation, and then gradually 241 increased further, up to 72 h, although some differences were observed between donors 1 and 242 2. Little change in the level of CRM1 was observed in the absence of stimulation. Actin was 243 used as a loading control, as its level remained relatively constant. These results indicate that 244 the CRM1 gene belongs to the class of early response genes that are induced during 245 lymphocyte activation.

246 We next measured the levels of CRM1 mRNA by quantitative RT-PCR to determine how 247 the expression of CRM1 is stimulated in PBMCs (Figure 1B). The amount of CRM1 248 transcript did increase, but the expression profile varied among individuals. For example, the 249 level of CRM1 mRNA observed in donor 3 was relatively constant up to 24 h after 250 stimulation and then started to increase, while the level of CRM1 mRNA in donor 1 gradually 251 increased over the course of activation. Nevertheless, we consistently found in 4 experiments 252 that the increase in CRM1 mRNA occurred after the increase in CRM1 protein. Specifically, 253 up to 4 h after stimulation, marked increases in the level of CRM1 protein were detected, in 254 contrast to nearly constant levels of CRM1 mRNA. Therefore, these results suggest that 255 during lymphocyte activation CRM1 production is initially stimulated post-transcriptionally 256 and then further enhanced by upregulating transcription.

In order to identify the signaling pathway responsible for the induction of CRM1
transcription, we activated PBMCs in the presence of various combinations of IL-2, calcium
ionophore, and PMA. As shown in Figure 1C, IL-2 and PMA fully induced CRM1 whereas
IL-2 and calcium ionophore did not. Next, we examined whether PMA alone is sufficient to
induce CRM1. PMA alone enhanced CRM1 production as efficiently as IL-2 plus PMA.

Since PMA is an activator of protein kinase C (PKC) (49), these data suggest that induction
of CRM1 is PKC dependent.

264 To confirm the above results, we examined the effect of various inhibitors including

staurosporine (a PKC inhibitor) (60) and cyclosporin (a Ca⁺⁺ cascade inhibitor) (66). As

shown in Figure 1D, staurosporine, but not cyclosporin, inhibited the induction of CRM1,

267 consistent with the results shown in Figure 1C. We further examined the effects of PDTC (an

268 NFkB inhibitor) (43) and PD98059 (a MAPKK inhibitor) (3) and found that PDTC inhibited

269 CRM1 induction at the highest dose, but PD98059 had only a minor effect.

270 **Regulated expression of CRM1 in CD4⁺ T lymphocytes.** To examine CRM1 regulation in

271 CD4⁺ T lymphocytes, resting CD4⁺ T lymphocytes were purified by negative selection and

activated by treatment with a combination of IL-2, ionophore, and PMA. CRM1 levels were

estimated by Western blotting (Figure. 2A). CRM1 expression was induced by the same

stimuli as in PBMCs, although the kinetics of induction was somewhat different among

275 donors. In contrast to CRM1, the level of actin was constant during T cell activation.

Staurosporine inhibited the enhanced production of CRM1 (data not shown), indicating the
involvement of PKC in the induction of CRM1 in CD4⁺ T cells.

278 To examine the mechanism underlying the stimulation of CRM1 in CD4⁺ T cells, we 279 measured the amount of CRM1 mRNA by quantitative RT-PCR (Figure 2B). Similar to 280 PBMCs, the amount of CRM1 mRNA also increased during CD4⁺ T cell activation. Although 281 the levels of CRM1 mRNA during T cell activation varied to some extent among donors, 282 similar profiles of induction were observed; after a lag of approximately 4 h, the level of 283 CRM1 mRNA started to increase and continued to do so for up to 24 h after stimulation. 284 These results suggest that the increase in CRM1 mRNA is delayed compared to the increase 285 in CRM1 protein, as seen in PBMCs. The level of CRM1 mRNA was constant at times 286 greater than 24 h post-stimulation, but purified CD4⁺ T cells appeared unhealthy 2 and 3 days 287 after stimulation in these cultures, as judged by microscopic observation. Therefore, further 288 examination is required to definitively determine the levels of CRM1 protein and mRNA in 289 CD4⁺ T cells at later times after stimulation.

290 Expression of hCRM1 in the Tg rat. The above results indicate that regulation of CRM1 291 expression during the activation of lymphocytes is complex. Considering the lack of 292 characterization of CRM1 regulatory elements, we used a BAC clone, which is likely to 293 harbor the entire regulatory and coding regions of the CRM1 gene, to establish an hCRM1-Tg 294 rat. One rat strain carrying the hCRM1 transgene was obtained from microinjection of the 295 hCRM1 containing BAC clone into 450 fertilized one-cell eggs from F344 female rats. We 296 assessed the expression of hCRM1 protein in each tissue by immunoblotting using hCRM1 297 specific antibody (22). As shown in Figure 3A, hCRM1 expression was detected in all organs 298 tested. The expression level of this protein was especially high in ovary and thymus compared 299 to other organs. In addition, expression levels of hCRM1 in the organs were similar to those 300 of endogenous rCRM1 (Figure 3B). hCRM1 expression was not detected in any organs 301 prepared from wild type rats (data not shown). These data indicate that the Tg rats express 302 hCRM1 in a physiologically relevant manner.

303 Enhanced production of p19 Gag in Tg-derived cell lines. To assess the replication of 304 HTLV-1 in T cells of hCRM1 Tg rats, we established several T cell lines from both Wt and 305 Tg rats by infecting with HTLV-1. Thymocytes and splenocytes isolated from Wt or hCRM1-306 Tg rats were co-cultured with the HTLV-1-infected human T cell line MT2, which had been 307 treated with mitomycin C and then maintained in culture medium containing 10 U/ml of IL-2. 308 After 2 months of cultivation, we obtained 6 lines from Wt rats and 11 from Tg rats (Table 1). 309 As shown in Figure 4, all of the Tg-derived cell lines were confirmed to have the hCRM1 310 gene (Figure 4A) and express hCRM1 (Figure 4B), whereas none of Wt-derived lines 311 contained the gene or the protein. The expression level of hCRM1 was different among the 312 cell lines.

313 We next examined the expression of cell surface markers, including CD3, CD4, CD5, CD8,

314 CD25, MHC-I, and MHC-II, in these cell lines (Table 1). All the cell lines expressed rat

315 CD25 and MHC-I, indicating that they were derived from rat cells, not from the human MT2

cells. Most of the cell lines also expressed rat CD5 and MHC-II, with the exception of 2 Wt

and 3 Tg-derived lines. Expression of rat CD3 was confirmed in 6 of 9 Tg lines, whereas only

318 2 of 6 lines were positive in the Wt lines. Rat CD4 expression was detected in 1 Wt and 6 Tg

319 cell lines. Rat CD8 was detected in 1 Wt and 1 Tg-derived line. As judged by the expression

of CD3, we established a total of 8 T cell lines, 2 from Wt and 6 from Tg rats.

We next examined the production of the p19 Gag protein in the cell lines to assess the effect

322 of hCRM1 on HTLV-1 replication. Our results demonstrated that the Tg-derived cell lines

323 produced much greater levels of p19 in the culture supernatant, compared to the Wt-derived

cells (Figure 4C). After 2 and 4 days in culture, the mean p19 production by 9 Tg-derived cell

325 lines was 1000 ± 10 and 10000 ± 100 times higher, respectively, than the mean production of

the 6 Wt-derived lines (Figure 4D). The amounts (1-60 ng/ml) of p19 released from the Tg-

327 derived cell lines are equivalent to human HTLV-1 producing T cell lines, such as MT2 and

328 MT4 (data not shown). These results clearly demonstrate the enhanced production of the

329 HTLV-1 Gag protein in the cells expressing hCRM1.

To further examine the increased p19 production in each cell line expressing hCRM1, we

conducted a FACS analysis to detect the intracellular Gag protein. As shown in Figure 4E, we

were able to detect p19 and the precursor p55 Gag protein in all cell lines derived from Tg
rats. In contrast, no Wt-derived cell lines produced detectable amounts of Gag. These results
further support the role of hCRM1 in the enhancement of HTLV-1 Gag production.

We also assessed the proliferation of each cell line to exclude the possibility that the enhanced production was not due to increased production by individual cells, but was the result of increases in the number of cells in the Tg-derived lines. As shown in Figure 4F, we confirmed that there was no difference in the proliferation rate between Wt- and Tg-derived cell lines after 2 or 4 days in culture. In addition, there was no correlation between the rate of cell growth and the amount of p19 in the culture in any cell line.

341 The state of HTLV-1 infection is not correlated with levels of p19 production. We also 342 assessed the proviral load of each cell line to rule out the possibility that enhanced production 343 of Gag was due to increased provirus numbers in Tg cell lines. Real-time PCR analysis using 344 a pair of primers for the Tax gene was performed to quantify the number of integrated 345 provirus. As a relative standard, we used genomic DNA from FPM1 cells, which contain 3 346 copies of HTLV-1 provirus per cell (36). As shown in Figure 5A, all 5 Wt cell lines contained 347 more than 2 copies of the provirus, whereas most of the Tg lines appeared to have only one 348 provirus per cell, with the exception of FCCT13-1 cells which possessed 4 copies. Thus, there 349 was no correlation between the provirus number and p19 production, indicating that 350 differences in the amount of provirus were not responsible for the enhanced Gag production 351 in Tg derived cells.

Altered expression of Tax and Rex could also be associated with enhanced expression of Gag in Tg-derived cells. Thus, we investigated the expression of Tax in the cell lines. As shown in Figure 5B, FACS analysis revealed that all of the cell lines tested expressed detectable levels of Tax proteins. Although we observed variations in the levels of Tax expression among the cell lines, there was no significant difference in the expression between Wt- and Tg-derived lines.

We next examined Rex expression by immunoblotting. As shown in Figure 5C, the Rex protein was expressed in all cell lines tested. Again, there was no statistical difference in the protein expression between Wt and Tg cells. Two Tg cell lines, FCMS1 and FCMS18,

361 expressed p21 protein as well as the p27 Rex. This expression was not associated with elevated expression of Gag, since the amounts of p19 Gag produced by these two cell lines 362 363 were similar to the other Tg-derived cell lines (Figure 4C, D). These results indicate that the 364 number of integrated provirus and the expression levels of Tax and Rex are not correlated 365 with the enhanced expression of Gag observed in cell lines derived from hCRM1-Tg rats. 366 Enhanced Dissemination of HTLV-1 in hCRM1 Tg rats. We next examined the 367 proliferation of HTLV-1 in Tg rats by inoculating animals with the HTLV-1 producing 368 human T cell line MT2 as a virus source. Analysis of plasma p19 concentration in the 369 infected rats over time did not show significant differences between Tg and Wt rats, although 370 the p19 concentration in Tg rats tended to be higher during the first 6 weeks after infection 371 (Figure 6A). Figure 6B shows the mean plasma p19 concentration in rats after 1 week of 372 infection and again demonstrates higher, but not significantly different, levels of the viral 373 protein in Tg-derived samples. To evaluate dissemination of the virus in vivo, we determined 374 the presence of HTLV-1 provirus DNA in various organs 1 week after intraperitoneal 375 infection by nested PCR that specifically amplifies a part of the px region. We calculated the 376 percentage of rats that sustained the px gene in 5 independent experiments, and found that the 377 rate with which the virus disseminated to the thymus in Tg rats was significantly higher than 378 that in Wt rats (Figure 6C). However, we have not detected notable differences between the 379 two groups in HTLV-1 proviral load detected in various organs including peripheral blood 380 cells and thymus (Figure 6D, E, and data not shown). These results indicate the limited 381 effects of hCRM1 in the proliferation of HTLV-1 in vivo, which are in dramatic contrast to 382 the significant enhancement of HTLV-1 production in Tg derived cells in vitro. 383 384 DISCUSSION 385 386 Unlike hCRM1, rCRM1 does not support Rex function due to its inability to induce Rex-387 Rex dimerization, which is required for RNA export from the nucleus to the cytoplasm (22). 388 This may be one reason why HTLV-1 replicates poorly in rats compared to humans. This

observation suggests the hCRM1-Tg rats would be novel animal models, since they would
support better replication of HTLV-1.

391 The essential role of CRM1 in cell viability suggested that proper expression of the 392 transgene would be a key for successful construction of Tg rats. Therefore, we examined the 393 expression pattern of CRM1 and found that CRM1 is expressed in a manner similar to the 394 early response genes induced during the activation of lymphocytes, including CD4⁺ T cells. 395 Our results suggest that expression of CRM1 is stimulated in two steps: in the first phase, 396 lasting approximately 4 h, induction is regulated primarily in a post-transcriptional manner, 397 and in the second phase, transcriptional augmentation takes place. Alternatively, CRM1 398 protein in PBMCs may be rapidly turned over and is then protected from degradation upon 399 stimulation, giving rise to the early increase in protein levels. The profile of CRM1 400 expression further suggests that the initial induction occurs in the G₁ phase of the cell cycle, 401 which is also supported by the observation that mimosine, which blocks the cell cycle in late 402 $G_1(65)$, does not prevent the induction (data not shown).

403 The elaborate regulation of CRM1 expression led us to use a BAC clone harboring the entire 404 hCRM1 gene for Tg rat construction. An initial unsuccessful trial using the mouse H2 405 promoter to express hCRM1 cDNA supports the necessity of using the hCRM1 BAC. Our 406 results indicate that the hCRM1 BAC Tg rats express hCRM1 in various organs including 407 thymus and spleen, in a manner similar to endogenous rCRM1 in rats. Moreover, the distribution of hCRM1 in the Tg rats is similar to that observed in humans (28, 37). Therefore, 408 409 use of the hCRM1 BAC construct may have resulted in physiological expression of the 410 protein in Tg rats. We also demonstrated hCRM1 expression in all Tg derived cell lines, 411 which will be useful for the functional analysis of hCRM1 in HTLV-1-infected cells. 412 We have previously reported that expression of hCRM1 induced an increase in HTLV-1 Gag production in both rat epithelial and T cells (21, 69). Our present study also showed that 413 414 T cell lines established from hCRM1-Tg rats produced significantly greater amounts of p19 415 than cell lines established from Wt rats, further indicating the positive effect of hCRM1 on 416 viral protein synthesis. This effect was not due to the effects of Tax or Rex proteins, which 417 enhance the transcription of total viral mRNAs and the nuclear export of unspliced and

418 incompletely spliced mRNAs, respectively (12, 26, 30, 68), since the expression levels of 419 these proteins were not significantly different between Tg and Wt cell lines. Additionally, 420 these results indicate that induction of hCRM1 expression does not affect the expression of 421 HTLV-1 regulatory proteins in virus-infected rat cells. We also observed variation in the 422 levels of p19 production among the cell lines derived from hCRM1-Tg rats. Since the amount 423 of p19 did not correlate with the expression levels of hCRM1, Tax, or Rex, the reason for the 424 variation is not clear. Some other factors, including RanGTP and RanBP3, which play 425 important roles in the nuclear export of CRM1-substrate complexes (14, 41, 47, 59), may 426 affect the levels of p19 production in the rat cell lines. It is also possible that the integration 427 sites of the provirus influence virus production. Further studies are required to identify the 428 factors that result in varying p19 production among Tg-derived cell lines.

429 Variation was also observed in the expression of cell surface proteins among the established 430 cell lines (Table 1). It is especially interesting that most of the wt-derived cells do not express 431 CD3 or CD4, whereas the majority of the Tg-derived lines possess both of these molecules. 432 Since others and we have established a number of CD4 positive cells from various strains of 433 wt rats (31, 36), the present results may be due to the experimental disparity. However, it is 434 possible that enhanced HTLV-1 production by the hCRM1 expressing cells and subsequent 435 dissemination of the virus in the culture may influence the phenotypes of the transformed 436 cells. Thus, additional studies are required to determine the significance and the cause of the 437 difference.

438 The Tg rats showed minimal effects on HTLV-1 replication in vivo. Since dramatic

439 enhancement of HTLV-1 production was observed in all hCRM1 expressing cells in vitro, it

440 is possible that the number of HTLV-1-infected cells in vivo was too low to detect

441 differences in virus production between Wt and Tg rats. From this point of view, alteration of

442 experimental condition to improve the initial infection rate of HTLV-1 may lead to the

443 enhanced viral replication in the Tg rats. Repression of viral protein expression in vivo may

444 also reduce the effects of hCRM1, masking the enhanced viral replication in the Tg rats. Such

445 responses have been well documented in HTLV-1 infected individuals (32, 33). It is also

446 possible that HTLV-1 specific immune responses could affect the replication of HTLV-1 in

the Tg rats. Indeed. Our preliminary experiments indicated that induction of HTLV-1-specific
CTL responses occurred as early as 1 week after virus infection. Alternatively, some other
host factors may govern and modulate efficient HTLV-1 replication in vivo. Thus, further
studies on both virological and immunological aspects are required to verify the importance

451 of the Tg rats as an in vivo model of HTLV-1 infection.

452 The HTLV-1 Rex protein is able to functionally replace the Rev protein of HIV-1 (57).

453 CRM1 is a nuclear export factor for HIV-1 Rev and a truncated Rev mutant with weakened

454 binding affinity to CRM1 results in reduced levels of HIV-1 Gag production (20). These

455 results raise the possibility that rat cells expressing hCRM1 protein can produce enhanced

456 levels of HIV-1 structural proteins. Indeed, our preliminary results demonstrate that hCRM1

457 promotes HIV-1 p24 Gag production in rat cells (unpublished observation). Thus, the

hCRM1-Tg rats generated in this study may be also useful as a small animal model of HIV-1
infection, when HIV-1 receptors are simultaneously expressed in these rats.

460 HIV latently infects reservoirs of resting T cells (7, 9, 10, 13, 61), which are thought to be in 461 the G₀ state, and the virus is then reactivated during T cell activation. Alternatively, HIV has 462 also been reported to propagate efficiently in non-replicating lymphatic T cells (18), which 463 lack certain markers specific for activation. Since cytokines levels are high in lymphatic 464 tissues, the progression of T cells from G_0 to G_1 may support HIV replication. Although 465 release from cell cycle block has been extensively investigated at the transcriptional level, a recent study has shown that the synthesis of unspliced HIV Gag RNA increases rapidly during 466 467 the HIV reactivation process, to a much greater extent than the synthesis of multiply spliced 468 RNAs (7). Our results demonstrating a rapid increase in CRM1 expression during lymphocyte 469 activation provide a clue to the underlying mechanism, the efficient action of the HIV Rev 470 protein, which leads to robust synthesis of unspliced RNA. We suggest that HIV gene 471 expression is regulated in lymphocytes at both the transcriptional and RNA export levels. 472 Independent of viral replication, the first phase of enhancement of CRM1 expression is also 473 coincident with the induction of cytokines, such as IL-2 (4). CRM1 interacts with the ARE 474 located in the 3' untranslated region of c-fos mRNA (via HuR and its ligands) and mediates

475 export of this mRNA from the nucleus to the cytoplasm (6, 16). Therefore, CRM1 may

476	transport cytokine mRNAs belonging to the early response genes since many cytokine					
477	mRNAs harbor ARE sequences (24, 56). Collectively, these observations suggest that					
478	enhancement of mRNA export via the induction of CRM1 expression, in addition to					
479	regulation at the transcriptional and translational levels, may play an important role in					
480	coordinating gene expression during lymphocyte activation. The existence of a post-					
481	transcriptional mechanism leading to a rapid increase in CRM1 protein is consistent with this					
482	hypothesis.					
483	In conclusion, we have established a novel Tg rat carrying the hCRM1 gene via examining					
484	its gene expression, and isolated several HTLV-1-infected T cell lines expressing hCRM1.					
485	Our results demonstrate that T cells from hCRM1 Tg rats produced enhanced levels of the					
486	HTLV-1 Gag protein compared to T cells from Wt control rats. These results indicate the					
487	essential role of hCRM1 in proper HTLV-1 replication and suggest the importance of this Tg					
488	rat in the development of HTLV-1 animal models. These animals may also contribute to the					
489	development of models for other human retroviruses, such as HIV-1.					
490						
491	ACKNOWLEDGEMENTS					
492						
493	Buffy coats for the isolation of lymphocytes were the kind gift of the Hokkaido Red Cross					
494	Blood Center (Sapporo, Japan). We thank A. Hirano, N. Mizuno, K. Nakajima and J. Hioki					
495	for excellent technical assistance. This study was supported by grants from the Ministry of					
496	Sports and Culture (Japan), and the Ministry of Health and Welfare (Japan).					
497						
498	REFERENCES					
499						
500	1. Adachi, Y., and M. Yanagida. 1989. Higher order chromosome structure is affected					
501	by cold-sensitive mutations in a Schizosaccharomyces pombe gene CRM1+ which					
502	encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J.					
503	Cell. Biol. 108:1195-1207.					

504	2.	Akagi, T., I. Takeda, T. Oka, Y. Ohtsuki, S. Yano, and I. Miyoshi. 1985.
505		Experimental infection of rabbits with human T-cell leukemia virus type I. Jpn. J.
506		Cancer Res. 76: 86-94.
507	3.	Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD
508		098059 is a specific inhibitor of the activation of mitogen-activated protein kinase
509		kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
510	4.	Ashwell, J. D., and R. D. Klusner. 1990. Genetic and mutational analysis of the T-
511		cell antigen receptor. Annu. Rev. Immunol. 8:139-167.
512	5.	Bogerd, H. P., R. A. Fridell, R. E. Benson, J. Hua, and B. R. Cullen. 1996. Protein
513		sequence requirements for function of the human T-cell leukemia virus type 1 Rex
514		nuclear export signal delineated by a novel in vivo randomization-selection assay.
515		Mol. Cell. Biol. 16:4207-4214.
516	6.	Brennan, C. M., I. E. Gallouzi, and J. A. Steitz. 2000. Protein ligands to HuR
517		modulate its interaction with target mRNAs in vivo. J. Cell Biol. 151:1-14.
518	7.	Brooks, D. G., S. G. Kitchen, C. M. Kitchen, D. D. Scripture-Adams, and J. A.
519		Zack. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-464.
520	8.	Callanan, M., N. Kudo, S. Gout, M. Brocard, M. Yoshida, S. Dimitrov, and S.
521		Khochbin. 2000. Developmentally regulated activity of CRM1/XPO1 during early
522		Xenopus embryogenesis. J. Cell Sci. 113:451-459.
523	9.	Chun, T. W., D. Engel, M. M. Berrey, T. Shea, L. Corey, and A. S. Fauci. 1998.
524		Early establishment of a pool of latently infected, resting CD4(+) T cells during
525		primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95:8869-8873.
526	10.	Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L.
527		Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent
528		reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA
529		94: 13193-13197.
530	11.	Daenke, S., S. Nightingale, J. K. Cruickshank, and C. R. Bangham. 1990.
531		Sequence variants of human T-cell lymphotropic virus type I from patients with

- tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological
 from leukemic isolates. J. Virol. 64:1278-1282.
- 534 12. Fang, J., S. Kushida, R. Feng, M. Tanaka, T. Kawamura, H. Abe, N. Maeda, M.
 535 Onobori, M. Hori, K. Uchida, and M. Miwa. 1998. Transmission of human T-cell
 536 leukemia virus type 1 to mice. J. Virol. 72:3952-3957.
- 537 13. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson,
- 538 T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M.
- Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a
 reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science
- **278:**1295-1300.
- Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export
 receptor for leucine-rich nuclear export signals. Cell 90:1051-1060.
- 544 15. Fornerod, M., J. van Deursen, S. van Baal, A. Reynolds, D. Davis, K. G. Murti, J.
- 545 Fransen, and G. Grosveld. 1997. The human homologue of yeast CRM1 is in a
- 546 dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88.
- 547 EMBO J. **16:**807-816.
- 548 16. Gallouzi, I. E., and J. A. Steitz. 2001. Delineation of mRNA export pathways by the
 549 use of cell-permeable peptides. Science 294:1895-1901.
- 550 17. Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. de
- 551 The. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical
 552 spastic paraparesis. Lancet 2:407-410.
- 553 18. Haase, A. T., K. Henry, M. Zupancic, G. Sedgewick, R. A. Faust, H. Melroe, W.
- 554 Cavert, K. Gebhard, K. Staskus, Z. Q. Zhang, P. J. Dailey, H. H. Balfour, Jr., A.
- 555 Erice, and A. S. Perelson. 1996. Quantitative image analysis of HIV-1 infection in
 556 lymphoid tissue. Science 274:985-989.
- 557 19. Hakata, Y., T. Umemoto, S. Matsushita, and H. Shida. 1998. Involvement of
- 558 human CRM1 (exportin 1) in the export and multimerization of the Rex protein of
- human T-cell leukemia virus type 1. J. Virol. **72:**6602-7.

560 20. Hakata, Y., M. Yamada, N. MAbuchi, and H. Shida. 2002. The carboxy-terminal 561 region of the human immunodeficiency virus type 1 protein Rev has multiple roles in 562 mediating CRM1-related Rev functions. J. Virol. 76:8079-89. 563 21. Hakata, Y., M. Yamada, and H. Shida. 2003. A multifunctional domain in human 564 CRM1 (exportin 1) mediates RanBP3 binding and multimerization of human T-cell 565 leukemia virus type 1 Rex protein. Mol. Cell. Biol. 23:8751-8761. 566 22. Hakata, Y., M. Yamada, and H. Shida. 2001. Rat CRM1 is responsible for the poor 567 activity of human T-cell leukemia virus type 1 Rex protein in rat cells. J. Virol. 568 **75:**11515-1525. 23. 569 Hall, W. W., C. R. Liu, O. Schneewind, H. Takahashi, M. H. Kaplan, G. Roupe, 570 and A. Vahlne. 1991. Deleted HTLV-I provirus in blood and cutaneous lesions of 571 patients with mycosis fungoides. Science 253:317-320. 572 24. Hamilton, T. A., Y. Ohmori, and J. Tebo. 2002. Regulation of chemokine 573 expression by antiinflammatory cytokines. Immunol. Res. 25:229-245. 25. 574 Hanabuchi, S., T. Ohashi, Y. Koya, H. Kato, A. Hasegawa, F. Takemura, T. 575 Masuda, and M. Kannagi. 2001. Regression of human T-cell leukemia virus type I 576 (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J. 577 Natl. Cancer Inst. 93:1775-1783. 578 26. Hidaka, M., J. Inoue, M. Yoshida, and M. Seiki. 1988. Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but 579 580 suppresses expression of regulatory proteins. EMBO J. 7:519-523. 581 27. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. I. Kinoshita, S. 582 Shirakawa, and I. Miyoshi. 1981. Adult T-cell leukemia: antigen in an ATL cell line 583 and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 584 **78:**6476-6480. 585 28. Holaska, J. M., and B. M. Paschal. 1998. A cytosolic activity distinct from CRM1 mediates nuclear export of protein kinase inhibitor in permeabilized cells. Proc. Natl. 586 Acad. Sci. USA 95:14739-14744. 587

- 588 29. Hoshino, H., H. Tanaka, K. Shimotohno, M. Miwa, M. Nagai, M. Shimoyama, 589 and T. Sugimura. 1984. Immortalization of peripheral blood lymphocytes of cats by 590 human T-cell leukemia virus. Int. J. Cancer **34:**513-517. 591 30. Inoue, J., M. Yoshida, and M. Seiki. 1987. Transcriptional (p40x) and post-592 transcriptional (p27x-III) regulators are required for the expression and replication of 593 human T-cell leukemia virus type I genes. Proc. Natl. Acad. Sci. USA 84:3653-3657. 594 31. Ishiguro, N., MAbe, K. Seto, H. Sakurai, H. Ikeda, A. Wakisaka, T. Togashi, M. 595 Tateno, and T. Yoshiki. 1992. A rat model of human T lymphocyte virus type I 596 (HTLV-I) infection. 1. Humoral antibody response, provirus integration, and HTLV-I-597 associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative 598 HTLV-I carrier rats. J. Exp. Med. 176:981-989. 599 32. Kannagi, M., S. Matsushita, and S. Harada. 1993. Expression of the target antigen 600 for cytotoxic T lymphocytes on adult T- cell-leukemia cells. Int. J. Cancer 54:582-588. 601 33. Kannagi, M., K. Sugamura, K. Kinoshita, H. Uchino, and Y. Hinuma. 1984. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from 602 603 an adult T cell leukemia/lymphoma patient. J. Immunol. 133:1037-1041. 604 34. Kim, F. J., A. A. Beeche, J. J. Hunter, D. J. Chin, and T. J. Hope. 1996. 605 Characterization of the nuclear export signal of human T-cell lymphotropic virus type 606 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic 607 interactions. Mol. Cell. Biol. 16:5147-5155. 608 35. Kinoshita, T., A. Tsujimoto, and K. Shimotohno. 1991. Sequence variations in 609 LTR and env regions of HTLV-I do not discriminate between the virus from patients 610 with HTLV-I-associated myelopathy and adult T-cell leukemia. Int. J. Cancer 47:491-611 495. 612 36. Koya, Y., T. Ohashi, H. Kato, S. Hanabuchi, T. Tsukahara, F. Takemura, K. 613 Etoh, M. Matsuoka, M. Fujii, and M. Kannagi. 1999. Establishment of a 614 seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats 615 inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially 616 expressing Tax. J. Virol. 73:6436-6443.
 - 22

617	37.	Kudo, N., S. Khochbin, K. Nishi, K. Kitano, M. Yanagida, M. Yoshida, and S.
618		Horinouchi. 1997. Molecular cloning and cell cycle-dependent expression of
619		mammalian CRM1, a protein involved in nuclear export of proteins. J. Biol. Chem.
620		272: 29742-29751.
621	38.	Kurihara, K., N. Harashima, S. Hanabuchi, M. Masuda, A. Utsunomiya, R.
622		Tanosaki, M. Tomonaga, T. Ohashi, A. Hasegawa, T. Masuda, J. Okamura, Y.
623		Tanaka, and M. Kannagi. 2005. Potential immunogenicity of adult T cell leukemia
624		cells in vivo. Int. J. Cancer 114:257-267.
625	39.	Kushida, S., H. Mizusawa, M. Matsumura, H. Tanaka, Y. Ami, M. Hori, K.
626		Yagami, T. Kameyama, Y. Tanaka, A. Yoshida, H. Nyunoya, K. Shimotohno, Y.
627		Iwasaki, K. Uchida, and M. Miwa. 1994. High incidence of HAM/TSP-like
628		symptoms in WKA rats after administration of human T-cell leukemia virus type 1-
629		producing cells. J. Virol. 68:7221-7226.
630	40.	LaGrenade, L., B. Hanchard, V. Fletcher, B. Cranston, and W. Blattner. 1990.
631		Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet
632		336: 1345-1347.
633	41.	Lindsay, M. E., J. M. Holaska, K. Welch, B. M. Paschal, and I. G. Macara. 2001.
634		Ran-binding protein 3 is a cofactor for CRM1-mediated nuclear protein export. J. Cell
635		Biol. 153: 1391-1402.
636	42.	Mann, D. L., P. DeSantis, G. Mark, A. Pfeifer, M. Newman, N. Gibbs, M.
637		Popovic, M. G. Sarngadharan, R. C. Gallo, J. Clark, W. Blattner. 1987. HTLV-I
638		associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science
639		236: 1103-1106.
640	43.	Martinez-Martinez, S., P. Gomez del Arco, A. L. Armesilla, J. Aramburu, C. Luo,
641		A. Rao, and J. M. Redondo. 1997. Blockade of T-cell activation by dithiocarbamates
642		involves novel mechanisms of inhibition of nuclear factor of activated T cells. Mol.
643		Cell. Biol. 17:6437-6447.
644	44.	Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi, K.
645		Nagata, and Y. Hinuma. 1981. Type C virus particles in a cord T-cell line derived by

- 646 co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature
 647 **294:**770-771.
- 648 45. Nakamura, H., M. Hayami, Y. Ohta, K. Ishikawa, H. Tsujimoto, T. Kiyokawa,
- M. Yoshida, A. Sasagawa, and S. Honjo. 1987. Protection of cynomolgus monkeys
 against infection by human T-cell leukemia virus type-I by immunization with viral
- 651 env gene products produced in Escherichia coli. Int. J. Cancer **40**:403-407.
- Makamura, H., Y. Tanaka, A. Komuro-Tsujimoto, K. Ishikawa, K. Takadaya, H.
 Tozawa, H. Tsujimoto, S. Honjo, and M. Hayami. 1986. Experimental inoculation
- of monkeys with autologous lymphoid cell lines immortalized by and producing
- human T-cell leukemia virus type-I. Int. J. Cancer **38:**867-875.
- 656 47. Nemergut, M. E., M. E. Lindsay, A. M. Brownawell, and I. G. Macara. 2002.
- Ran-binding protein 3 links CRM1 to the Ran guanine nucleotide exchange factor. J.
 Biol. Chem. 277:17385-17388.
- 659 48. Nishioka, K., I. Maruyama, K. Sato, I. Kitajima, Y. Nakajima, and M. Osame.
- 660 1989. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1:441.
- 49. Nishizuka, Y. 1984. The role of protein kinase C in cell surface signal transduction
 and tumour promotion. Nature 308:693-698.
- 663 50. Nomura, M., T. Ohashi, K. Nishikawa, H. Nishitsuji, K. Kurihara, A. Hasegawa,
- 664 R. A. Furuta, J. Fujisawa, Y. Tanaka, S. Hanabuchi, N. Harashima, T. Masuda,
- and M. Kannagi. 2004. Repression of tax expression is associated both with
- resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-
- specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J.
 Virol. 78:3827-3836.
- 669 51. Ohashi, T., S. Hanabuchi, H. Kato, Y. Koya, F. Takemura, K. Hirokawa, T.
- 670 Yoshiki, Y. Tanaka, M. Fujii, and M. Kannagi. 1999. Induction of adult T-cell
- 671 leukemia-like lymphoproliferative disease and its inhibition by adoptive
- 672 immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell
- 673 leukemia virus type 1-immortalized cells. J. Virol. **73:**6031-6040.

674	52.	Ohashi, T., S. Hanabuchi, H. Kato, H. Tateno, F. Takemura, T. Tsukahara, Y.						
675		Koya, A. Hasegawa, T. Masuda, and M. Kannagi. 2000. Prevention of adult T-cell						
676		leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells						
677		from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA						
678		vaccine. J. Virol. 74:9610-9616.						
679	53.	Oka, T., H. Sonobe, J. Iwata, I. Kubonishi, H. Satoh, M. Takata, Y. Tanaka, M.						
680		Tateno, H. Tozawa, S. Mori, T. Yoshiki and Y. Ohtsuki 1992. Phenotypic						
681		progression of a rat lymphoid cell line immortalized by human T-lymphotropic virus						
682		type I to induce lymphoma/leukemia-like disease in rats. J. Virol. 66:6686-6694.						
683	54.	Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto,						
684		and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet						
685		1: 1031-1032.						
686	55.	Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C.						
687		Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and						
688		cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad.						
689		Sci. USA 77: 7415-7419.						
690	56.	Raghavan, A., R. L. Robison, J. McNabb, C. R. Miller, D. A. Williams, and P. R.						
691		Bohjanen. 2001. HuA and tristetraprolin are induced following T cell activation and						
692		display distinct but overlapping RNA binding specificities. J. Biol. Chem. 276:47958-						
693		47965.						
694	57.	Rimsky, L., J. Hauber, M. Dukovich, M. H. Malim, A. Langlois, B. R. Cullen,						
695		and W. C. Greene. 1988. Functional replacement of the HIV-1 rev protein by the						
696		HTLV-1 rex protein. Nature 335: 738-740.						
697	58.	Simpson, R. M., T. M. Zhao, B. S. Hubbard, S. Sawasdikosol, and T. J. Kindt.						
698		1996. Experimental acute adult T cell leukemia-lymphoma is associated with thymic						
699		atrophy in human T cell leukemia virus type I infection. Lab. Invest. 74:696-710.						
700	59.	Stade, K., C. S. Ford, C. Guthrie, and K. Weis. 1997. Exportin 1 (CRM1p) is an						
701		essential nuclear export factor. Cell 90:1041-1050.						

702	60.	Stein, G. M., U. Pfuller, M. Schietzel, and A. Bussing. 2000. Expression of
703		interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins
704		in human peripheral blood mononuclear and tumor cells. Cytometry 41: 261-270.
705	61.	Stevenson, M., T. L. Stanwick, M. P. Dempsey, and C. A. Lamonica. 1990. HIV-1
706		replication is controlled at the level of T cell activation and proviral integration.
707		EMBO J 9: 1551-1560.
708	62.	Taguchi, H., T. Sawada, A. Fukushima, J. Iwata, Y. Ohtsuki, H. Ueno, and I.
709		Miyoshi. 1993. Bilateral uveitis in a rabbit experimentally infected with human T-
710		lymphotropic virus type I. Lab. Invest. 69:336-339.
711	63.	Tanaka, Y., A. Yoshida, H. Tozawa, H. Shida, H. Nyunoya, and K. Shimotohno.
712		1991. Production of a recombinant human T-cell leukemia virus type-I trans-activator
713		(tax1) antigen and its utilization for generation of monoclonal antibodies against
714		various epitopes on the tax1 antigen. Int. J. Cancer 48:623-630.
715	64.	Tateno, M., N. Kondo, T. Itoh, T. Chubachi, T. Togashi, and T. Yoshiki. 1984.
716		Rat lymphoid cell lines with human T cell leukemia virus production. I. Biological
717		and serological characterization. J. Exp. Med. 159:1105-1116.
718	65.	Wang, G., R. Miskimins, and W. K. Miskimins. 2000. Mimosine arrests cells in G1
719		by enhancing the levels of p27 (Kip1). Exp. Cell Res. 254:64-71.
720	66.	Werlen, G., E. Jacinto, Y. Xia, and M. Karin. 1998. Calcineurin preferentially
721		synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes.
722		EMBO J. 17: 3101-3111.
723	67.	Yoshida, M., M. Osame, K. Usuku, M. Matsumoto, and A. Igata. 1987. Viruses
724		detected in HTLV-I-associated myelopathy and adult T-cell leukaemia are identical on
725		DNA blotting. Lancet 1:1085-1086.
726	68.	Yoshida, M., T. Suzuki, J. Fujisawa, and H. Hirai. 1995. HTLV-1 oncoprotein tax
727		and cellular transcription factors. Curr. Top. Microbiol. Immunol. 193:79-89.
728	69.	Zhang, X., Y. Hakata, Y. Tanaka, and H. Shida. 2006. CRM1, an RNA transporter,
729		is a major species-specific restriction factor of human T cell leukemia virus type 1
730		(HTLV-1) in rat cells. Microbes Infect. 8:851-859.

732 FIGURE LEGENDS

733

734 Figure 1. Expression of CRM1 during activation of PBMCs. (A) PBMCs isolated from donor 735 1 and donor 2 were activated with ionophore, PMA, and IL-2 and analyzed by Western 736 blotting. (B) PBMCs isolated from donor 1 (\Box) and donor 3 (\diamondsuit) were activated with 737 ionophore, PMA, and IL-2 and analyzed by quantitative RT-PCR. Each value is the average 738 of duplicate measurements. (C) PBMCs isolated from donor 2 were activated with various 739 combinations of ionophore, PMA, and IL-2 and analyzed by Western blotting. (D) PBMCs 740 isolated from donor 2 were activated in the presence of various inhibitors and analyzed by 741 Western blotting. 742 Figure 2. Time course of CRM1 induction during activation of CD4⁺ T cells. (A) CD4⁺ T 743 744 cells isolated from donor 1 and donor 4 were activated with ionophore, PMA, and IL-2 and 745 analyzed by Western blotting. (B) Time course of CRM1 mRNA induction during activation 746 of CD4⁺ T cells. CD4⁺ T cells isolated from donor 1 (\Box) and donor 4 (\diamondsuit) were activated 747 with ionophore, PMA, and IL-2 and analyzed by quantitative RT-PCR. Each value is the 748 average of duplicate measurements. 749

Figure 3. Tissue distribution of human and rat CRM1 in hCRM1 Tg rats. (A) Immunoblot assays showing the relative levels of h and rCRM1 in rat tissues. Each protein level was determined on immunoblots containing 10 µg of total protein per lane. An FCMT18 cell extract was used as a positive control. (B) Relative levels of h/rCRM1 expression among organs are shown. Protein expression was quantified by ImageGauge software and relative values are normalized to the amount of actin.

756

Figure 4. Expression of HTLV-1 Gag and hCRM1 in the cell lines immortalized with HTLV1. (A) Detection of the hCRM1 transgene in the cell lines by PCR. DNA extracted from each
cell line (100 ng) was subjected to PCR with the primers for hCRM1 and for G3PDH as an

760 internal control. (B) Protein expression of hCRM1 was detected by immunoblotting. Samples (10 µg of total protein per each lane) were subjected to SDS-PAGE. HeLa cell extract was 761 762 used as a positive control. (C) HTLV-1 Gag protein in the supernatant of 2 day and 4 day 763 cultures was quantified by HTLV-1 p19 ELISA. The results are shown as the mean of three 764 independent experiments. (D) Based on the data of (C), the average p19 Gag production of Tg 765 and Wt cell lines was calculated. (E) The amount of intracellular Gag in each cell line was 766 analyzed by flow cytometry. Open histograms indicate the cells stained with anti p19/p55 767 Gag MAbs. Solid histograms represent the cells stained with control mouse IgG. (F) Growth 768 rate of Wt or Tg cell lines was measured. In parallel with the experiments described in Figure 769 4(C), the growth rate was monitored by the cell counting Kit-8 (Dojinndo Laboratories). The 770 relative cell numbers of 2 or 4 day vs. 0 day cultures are shown.

771

772 Figure 5. Viral states in HTLV-1-transformed T cells derived from Tg and wild type rats. (A) 773 Proviral load of each cell line was measured by quantitative real time PCR. The copy number 774 of HTLV-1 provirus was normalized by dividing with the G3PDH copy number in the same 775 sample. (B) Production of intracellular Tax in each cell line was analyzed by flow cytometry. 776 Solid histograms indicate the cells stained with anti-Tax MAb. Open histograms represent the 777 cells stained with control mouse IgG. (C) Rex expression of each cell line was detected by 778 immunoblotting. Ten µg of total protein per each lane was subjected to SDS-PAGE. Lower 779 bands in FCMS1 and TCMS18 samples represent p21 Rex.

780

781 Figure 6. Dissemination of HTLV-1 in hCRM1 Tg rats. (A) Mean plasma p19 concentration 782 in Wt (n=9; \bullet) or hCRM1 (n=7; \blacksquare) Tg rats after intraperitoneal inoculation of mitomycin C-treated MT2 cells ($1x10^7$ per animal). (B) Mean plasma p19 concentration in Wt (n=16; 783 784 \Box) or hCRM1-Tg (n=17; \blacksquare) rats 1 week after intraperitoneal inoculation of MT2 cells $(5x10^{6} \text{ per animal})$. (C) Detection of HTLV-1 provirus in thymus derived from rats used in 785 786 (B). Presence of HTLV-1 provirus was analyzed by nested PCR. Results are mean percentage 787 of HTLV-1 provirus positive rats in 5 independent experiments. (D and E) HTLV-1 proviral 788 loads of rats used in (B). HTLV-1 proviral loads in peripheral blood cells (D) or thymus (E)

- 789 were quantified by real-time PCR. The relative copy numbers of HTLV-1 provirus per 2×10^7
- copies of G3PDH are shown. Results are expressed as mean + standard deviation. The
- statistical significance of differences was determined with the Student's t-test, using
- 792 Microsoft Excel 2004 for Mac software, as indicated in Figure 6B-E.

Cell lines	hCRM1	1 Surface markers						
		CD3	CD4	CD5	CD8	CD25	MHC1	MHC2
FWT1	-	+	+	+	-	+	+	+
FWS1-11	-	-	-	+	-	+	+	+
FWS1-27	-	-	-	+	-	+	+	+
FWS1-31	-	-	-	+	(+)	+	+	-
FWS1-34	-	-	-	+	-	+	+	-
FWT11	-	+	-	+	-	+	+	+
FCMS1	+	+	+	+	-	+	+	(+)
FCMT1	+	+	+	+	-	+	+	+
FCMT18	+	+	+	-	-	+	+	-
FCMS18	+	+	+	(+)	-	+	+	(+)
FCMT27	+	+	+	(+)	-	+	+	(+)
FCCT13-1	+	-	-	(+)	-	+	+	+
FCCT13-2	+	+	-	(+)	(+)	+	+	+
FCCS13-1	+	-	-	-	-	+	+	+
FCCS13-2	+	-	(+)	(+)	-	+	+	-

812 +:positive (+):weakly positive -:negative













Relative cell number



Fig.5

